NEWS RELEASE

Teijin Pharma to Launch Japan-market Salesof Abaloparatide Acetate for Osteoporosis
Tokyo, Japan, January 30, 2023 --- Teijin Pharma Limited, the core company of theTeijin Group’s healthcare business, announced today that on January 30 the company
will begin selling abaloparatide acetate for osteoporosis under the tradename
OSTABALO® Subcutaneous Injection Cart 1.5mg will be priced at JPY 16,128.

The drug, which Teijin Pharma is positioning as a strategic product for robust market
penetration, is a new osteoplasty accelerator that embodies the company’s extensive
experience with treatments for bone and joint diseases.
OSTABALO® Subcutaneous Injection Cart 1.5mg is a self-administration drug indicated forpatients with osteoporosis at high risk of fractures. The active ingredient is abaloparatideacetate, a polypeptide containing a modification of one part of the 34 amino acidsequences from the N-terminus of human parathyroid hormone-related protein.
Abaloparatide acetate selectively stimulates RG-type parathyroid hormone type 1
receptors involved in bone metabolism. It is a novel bone anabolic agent with apredominant effect on bone formation over bone resorption, helping to prevent bonefractures. The drug can be taken once daily (80μg) by adults for up to 18 months,
administered subcutaneously via aqueous injection (cartridge) using an exclusiveelectronic injector, named the OSTABALO® Injector.
The efficacy and safety of abaloparatide acetate have been confirmed in clinical trials inJapan and worldwide involving osteoporosis patients with high risk of bone fractures. In
April 2017, the U.S. Food and Drug Administration (FDA) granted approval to Radius
Health, Inc. for the use of abaloparatide under the trade name of Tymlos® in U.S. intreating osteoporosis in postmenopausal women who are at high risk of fracture. For
deployment in Japan, Teijin Limited, the parent company of Teijin Pharma, signed alicense agreement with Radius in July 2017 and the two companies have been partneringfor development and sales in Japan for OSTABALO®.

According to a medical literature “2015 Guidelines for Prevention and Treatment ofOsteoporosis,” Japan is estimated to have about 13 million patients with osteoporosis,
many of whom are at risk of bone fractures that could greatly reduce their activities ofdaily living and quality of life. Osteoporosis is particularly troublesome for those with lowbone density, bone fragility or a high frequency of fractures due to aging. There is strong
demand in Japan for therapeutic drugs capable of increasing bone mass quickly to help
patients avoid debilitating bone fractures.
Teijin Pharma is helping to improve patients’ quality of life through solutions that address
problems with bones and joints, including through the company’s osteoporosis drugs
ONEALFA® and BONALON® (*) and sonic accelerated fracture healing system SAFHS®.
Teijin Pharma is committed to enhancing patients’ quality of life by providing newtreatment options for diseases with high unmet needs.
(*) BONALON® : Registered Trademark of NV Organon

About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in thefields of environmental value; safety, security and disaster mitigation; and demographic
change and increased health consciousness. Originally established as Japan's firstrayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing
three core business domains: high-performance materials including aramid, carbon
fibers and composites, and also resin and plastic processing, films, polyester fibers andproducts converting; healthcare including pharmaceuticals and home healthcare
equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing
care and pre-symptomatic healthcare; and IT including B2B solutions for medical,
corporate and public systems as well as packaged software and B2C online services for
digital entertainment. Deeply committed to its stakeholders, as expressed in the brandstatement “Human Chemistry, Human Solutions,” Teijin aims to be a company thatsupports the society of the future. The group comprises some 170 companies andemploys some 20,000 people across 20 countries worldwide. Teijin posted consolidated
sales of JPY 926.1 billion (USD 7.2 billion) and total assets of JPY 1,207.6 billion (USD9.4 billion) in the fiscal year that ended on March 31, 2022
Please visit www.teijin.com
Press Contact
Investor and Public Relations Department
Teijin Limited+81 (0)3 3506 4055
pr@teijin.co.jp